Antitrust Antitrust

Allergan and other drugmakers see UK dominance-abuse findings over hydrocortisone upheld in court

By Simon Zekaria
  • 18 Sep 2023 18:30
  • 18 Sep 2023 18:30
Drugmaker Allergan and peers have failed to overturn a UK decision that several firms abused their market dominance in the pricing of hydrocortisone tablets — representing a major boost for enforcers in a drive against pharmaceutical sector abuses.
The defendants overall fought more than 260 million pounds ($320 million) in

To view the latest version of this document and thousands of others like it, sign-in to MLex or register for a free trial.

Simon Zekaria

Senior Correspondent

Simon Zekaria is a senior correspondent in London, covering UK regulation. Prior to joining MLex, Simon reported on business news for The Wall Street Journal, including on telecommunications, media, technology and consumer affairs. Simon was also a writer for the WSJ on diverse subjects such as Brexit, UK politics and global sport. Simon was previously a correspondent on competition issues and European politics for Thomson Reuters and Agence France-Presse in Brussels. Simon is a graduate of Edinburgh University, with Masters degrees in literature and law. A French speaker, he has studied at the Sorbonne University, Paris.

Discover MLex

Stay on top of global regulatory developments

Latest News